What Syndicate Bio does

Syndicate Bio is a privately held genomics and precision medicine company founded in 2023 by Abasi Ene-Obong (formerly of 54gene) and operating dual hubs in Newark, Delaware, USA and Lagos, Nigeria. The company operates two go-to-market platforms: Direct by Syndicate Bio, a direct-to-consumer health portal offering an 18-product genetic testing catalog including non-invasive prenatal testing (NIPT), hereditary cancer panels (23-gene to ~300-gene tiers), the OncoMap130 solid tumor and OncoMap90 myeloid oncology panels, pharmacogenomics, and wellness testing, all priced in Nigerian Naira (₦350,000–₦1,500,000); and the Precision54 Clinical Hub, a B2B platform connecting pharmaceutical and biotechnology companies to pre-qualified clinical research sites across Africa for collaborative precision medicine studies.

Underlying technology is next-generation sequencing (NGS) combined with AI/ML analytics applied across multi-omics disciplines (genomics, proteomics, metabolomics, bioinformatics). Syndicate Bio operates an ISO 9001:2015- and ISO 15189:2022-compliant laboratory and positions itself around the genetic diversity of African populations, including Africa-prevalent conditions such as sickle cell disease, thalassemia, G6PD deficiency, and hereditary amyloidosis. Revenue is generated through one-time per-test fees from consumers and healthcare providers (with provider pricing approximately 5% below DTC rates) plus professional-services revenue from pharma/biotech research collaborations. The company's October 2025 Cancer Genome Nigeria Study with NICRAT — analyzing 442 variants across 41 genes in 50 tumors and identifying distinctive ALK and FGFR4 enrichments — establishes its foundational proprietary dataset.

Name

Syndicate Bio

Legal name

Syndicate Bio

Website

https://syndicate.bio

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Syndicate Bio is a genomics and precision medicine company that sells clinical-grade genetic testing directly to Nigerian consumers and healthcare providers through its Direct platform, and operates the Precision54 Clinical Hub to connect pharma and biotech partners to African clinical research sites.

Ownership category

akta.pro rank

Product category

Genetic Testing & Genomic Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Genetic testing services
• Clinical genomics platform
• Precision medicine solutions
• Cancer genomic profiling
• Non-invasive prenatal testing

Headquarters

HQ city

Newark

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D

Revenue model

1. Direct-to-Consumer Genetic Testing: Individual consumers purchase genomic tests directly through the Direct platform, including NIPT, hereditary cancer panels, pharmacogenomics, and wellness tests. Tests are priced at various tiers with provider and consumer pricing options.
2. Healthcare Provider Testing Services: Oncologists, hospitals, and clinics order tests for patients, receiving clinical-grade reports with actionable guidance. Pricing differs from direct consumer rates (approximately 5% lower for providers).
3. Pharma/Biotech Research Partnerships: Collaborative data projects, clinical studies, and sponsored testing for pharmaceutical and biotech companies through the Precision54 Clinical Hub. Enables pharma partners to access African genetic diversity for drug discovery and development.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Syndicate Bio sells clinical-grade genetic testing services — including NIPT, hereditary cancer panels, hereditary conditions tests, pharmacogenomics, wellness tests, and oncology tumor profiling (OncoMap130, OncoMap90) — through its Direct by Syndicate Bio consumer portal and through healthcare provider channels. The company also operates the Precision54 Clinical Hub, a B2B research network platform enabling pharmaceutical and biotech companies to run precision medicine studies and access pre-qualified clinical sites across Africa. All products are anchored in African-population genomic data and ISO-certified laboratory quality standards.

Product overview

Syndicate Bio is a global genomics and precision medicine company offering a comprehensive portfolio of genetic testing products through its Direct by Syndicate Bio portal. The core offering includes clinical genetic tests organized into three flagship categories: Hereditary Conditions Tests (90+ genes for blood, heart, neurological, metabolic conditions), Hereditary Cancer Tests (ranging from focused 23-50 gene panels to comprehensive ~300 gene panels), and Health & Wellness Tests (80+ genes). The company also provides specialized oncology solutions including OncoMap130 (solid tumor profiling) and OncoMap90 (myeloid cancer panel), as well as Non-Invasive Prenatal Testing (NIPT) with four tiers from gender-only to Plus with microdeletion screening. The Precision54 Clinical Hub provides pharmaceutical and biotech partners with access to pre-qualified research sites across Africa. All tests are designed with African genetic diversity in mind, including variants common in Nigerian and broader African populations.

Differentiator

Problem solved

Functional benefit

Brands

• Precision54: Clinical hub and network for accessing cutting-edge research and pre-qualified clinical trial sites in Africa.
• Direct by Syndicate Bio

Products and services

• Direct by Syndicate Bio Personal health portal that allows individuals to order genetic tests online, view results securely, and access optional genetic counseling and the Second Opinion Service. Targets health-conscious consumers in Africa seeking direct access to clinical-grade genomic testing.
• Precision54 Clinical Hub B2B research network platform connecting pharmaceutical and biotechnology companies with pre-qualified clinical research sites across Africa. Enables collaborative clinical studies, sponsored testing, and data projects with faster study startup times, giving pharma partners access to African genetic diversity for drug discovery and precision medicine research.
• NIPT (Non-Invasive Prenatal Test) Non-invasive prenatal test analyzing fetal DNA from maternal blood to screen for chromosomal conditions including Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13). Performed from 10 weeks of pregnancy with no miscarriage risk. Targets expectant parents seeking safe prenatal screening.
• NIPT Gender Entry-level non-invasive prenatal test providing accurate fetal gender determination and fetal fraction estimation from 10 weeks of pregnancy. Priced at ₦350,010 direct-to-consumer.
• NIPT Basic Basic NIPT screening for Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome) with gender determination from 10 weeks of pregnancy. Priced at ₦350,000 direct-to-consumer.
• NIPT Standard Comprehensive NIPT screening expanding coverage beyond NIPT Basic to include 6 sex chromosome aneuploidies, 19 additional autosomal aneuploidies, and fetal fraction estimation. Priced at ₦500,000 direct-to-consumer.
• NIPT Plus Most comprehensive NIPT option covering all Standard features plus 60+ microdeletion and duplication syndromes including Jacobsen syndrome and DiGeorge syndrome. Priced at ₦800,000 direct-to-consumer.
• Hereditary Conditions Test Clinical-grade genetic test screening 90+ genes for inherited conditions including sickle cell disease, G6PD deficiency, thalassemia, hereditary amyloidosis, and other blood, heart, nerve, immune, metabolic, and eye conditions. Targets individuals and providers seeking diagnostic insight into inherited disease risk.
• Health & Wellness Test Wellness-focused genetic test analyzing 80+ genes for personalized insights into nutrition, metabolism, fitness, skin health, allergies, detoxification, and sleep patterns. Priced at ₦450,000 direct-to-consumer.
• Pharmacogenomics Test Pharmacogenomic test revealing how an individual's genes affect response to drugs across cardiology, psychiatry, oncology, and pain management. Covers CYP2D6, CYP2C19, DPYD, TPMT, and other pharmacogenetic markers. Pricing not publicly disclosed.
• Hereditary Breast and Ovarian Cancer Test Focused hereditary cancer panel analyzing BRCA1/2, PALB2, CHEK2, and other genes (50 genes total) for inherited breast and ovarian cancer risk. Pricing not publicly disclosed.
• Hereditary Prostate Cancer Test Hereditary cancer panel screening 23 genes including BRCA1/2 and HOXB13 for inherited prostate cancer risk, with relevance to African populations. Pricing not publicly disclosed.
• Hereditary Pancreatic Cancer Test Hereditary cancer test analyzing 32 genes including BRCA1/2, PALB2, CDKN2A, and STK11 for inherited pancreatic cancer risk. Pricing not publicly disclosed.
• Hereditary Colorectal Cancer Test Hereditary cancer panel screening 44 genes linked to Lynch syndrome, familial adenomatous polyposis (FAP), and other hereditary colorectal cancers. Pricing not publicly disclosed.
• Comprehensive Hereditary Cancer Test One of the most comprehensive hereditary cancer panels in Africa, covering ~300 genes across 13+ organ systems including breast, ovarian, colorectal, prostate, pancreatic, gastric, melanoma, and endocrine tumors. Priced at ₦750,000 direct-to-consumer and ₦712,500 for providers.
• OncoMap130 Comprehensive 130-gene solid tumor profiling panel detecting clinically actionable mutations across lung, breast, colorectal, prostate, and ovarian cancers. Includes pharmacogenetic markers (DPYD, TPMT, NUDT15) for chemotherapy toxicity prevention and complete MSI marker coverage for immunotherapy decisions. Supports targeted therapy selection and clinical trial enrollment.
• OncoMap90 90-gene panel specifically designed for myeloid malignancies including AML (acute myeloid leukemia), MDS (myelodysplastic syndromes), and MPN (myeloproliferative neoplasms). Provides critical insight into prognosis, targeted therapy selection, and clinical trial eligibility. Priced at ₦900,000 direct-to-consumer and ₦855,000 for providers.
• Complete Genetic Health Package Premium bundled package combining the Hereditary Conditions Test, Comprehensive Hereditary Cancer Test, and Health & Wellness Test in a single offering with cost savings of ₦450,000 versus purchasing separately. Priced at ₦1,500,000 direct-to-consumer and ₦1,425,000 for providers.

Quantifiable outcome

• 442 variants analyzed across 50 tumors and 41 genes in first national Nigerian cancer genomics study
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Two partnerships are on record, tiered core and minor.

• National Institute for Cancer Research and Treatment (NICRAT) NigeriacoreStrategic or Co-development Partner · 1 October 2025Collaborative partnership for the Cancer Genome Nigeria Study - the first systematic genomic profiling of Nigerian cancers. The study analyzed 442 variants across 41 genes in 50 tumors, revealing both global drivers and distinctive enrichments (ALK, FGFR4) specific to Nigerian populations. 80% of variants classified as clinically significant. Joint whitepaper authored and released October 2025 outlining policy recommendations for integrating precision oncology into Nigeria's healthcare system.
• Precision54 Network CollaboratorsminorOthersThe company's website displays logos of 'Organizations supporting our mission' with 12 collaborator images, but specific partner names are not individually identified. These appear to be healthcare providers, research institutions, and industry partners participating in the Precision54 network.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• 54gene: Nigerian genomics startup founded by the same founder (Abasi Ene-Obong). The most direct comparable as a prior African-focused genomics venture with similar precision-medicine mission; serves as both a precedent and a potential cautionary benchmark.
• Color Health: Population genomics company offering hereditary cancer screening, pharmacogenomics, and DTC testing with strong pharma partnerships. Closely comparable business model combining clinical-grade panels, DTC access, and enterprise pharma data programs.
• Helix: DNA testing platform combining clinical genomics, health systems, and research partnerships. Comparable in operating a sequencing platform that serves both consumers and pharma/research customers through a network model.
• 23andMe: DTC genetic testing leader with health and ancestry reports. Comparable consumer-facing genetic testing model and brand-led marketing, though focused on US/European populations without African-specific panels.

Broad incumbents

• Natera: Large-scale genetic testing company with reproductive health (NIPT) and oncology offerings. Overlaps directly with Syndicate Bio's NIPT and OncoMap panels; significantly larger with established US clinical footprint.
• Myriad Genetics: Established leader in hereditary cancer testing (BRCA1/2, comprehensive panels). Direct overlap with Syndicate Bio's hereditary cancer panel strategy but with vastly larger scale and pharma partnerships.
• Invitae: Comprehensive genetic testing company spanning hereditary cancer, reproductive, and rare disease. Comparable breadth of menu and provider-facing clinical reports; competes on scale and reimbursement infrastructure.
• Foundation Medicine: Somatic cancer genomic profiling leader (Roche subsidiary). Direct overlap with Syndicate Bio's OncoMap130/OncoMap90 panels and pharma data partnership model; vastly larger reference database and pharma relationships.

Regional players

• Lancet Laboratories: Pan-African clinical laboratory network headquartered in South Africa. Comparable clinical lab infrastructure across Africa but broader routine diagnostics focus rather than specialty genomics.

Emerging players

• Mammoth Biosciences: Genomics platform company leveraging new sequencing technologies with disease detection applications. Comparable emerging-stage genomics platform with pharma partnerships and multi-omics ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/syndicate-bio
• Instagraminstagram.com/syndicate.bio

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syndicate Bio